MedTrace Logo

A Clinical Trial Aimed At Assessing the Efficacy and Safety of VT-101 for the Treatment of Non-muscle Invasive Bladder Cancer

NCT06632964 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2024-10-09

No results posted yet for this study

Summary

This is an experimental study to evaluate the efficacy and safety of VT-101 for the treatment of non-muscle invasive bladder cancer

Conditions

Interventions

BIOLOGICAL

Recombinant oncolytic adenovirus injection solution of VT-101

Active ingredient: VT-101 recombinant oncolytic adenovirus Specifications: 2×10\^10 IFU/ml, 0.5ml/ capsule Method of administration: intravesical perfusion

Sponsors & Collaborators

  • Xuzhou Medical University

    collaborator OTHER

  • The Affiliated Hospital of Xuzhou Medical University

    lead OTHER

Principal Investigators

  • Meng Lu, Ph.D · The Affiliated Hospital of Xuzhou Medical University

  • Junnian Zheng, M.D/Ph.D · The Affiliated Hospital of Xuzhou Medical University

  • Hailong Li, M.D/Ph.D · The Affiliated Hospital of Xuzhou Medical University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-18
Primary Completion
2025-09-01
Completion
2025-10-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06632964 on ClinicalTrials.gov